238 related articles for article (PubMed ID: 34098030)
1. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study.
Rischin D; King M; Kenny L; Porceddu S; Wratten C; Macann A; Jackson JE; Bressel M; Herschtal A; Fisher R; Fua T; Lin C; Liu C; Hughes BGM; McGrath M; McDowell L; Corry J
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):876-886. PubMed ID: 34098030
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
[TBL] [Abstract][Full Text] [Related]
4. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
[TBL] [Abstract][Full Text] [Related]
5. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103
Rischin D; Mehanna H; Young RJ; Bressel M; Dunn J; Corry J; Soni P; Fulton-Lieuw T; Iqbal G; Kenny L; Porceddu S; Wratten C; Robinson M; Solomon BJ;
Ann Oncol; 2022 Aug; 33(8):804-813. PubMed ID: 35525376
[TBL] [Abstract][Full Text] [Related]
6. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
7. Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01).
Xu T; Shen C; Zhou X; Zhu L; Xiang J; Wang Y; Zhu Y; He X; Ying H; Wang Y; Ji Q; Hu C; Lu X
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):169-178. PubMed ID: 37574169
[TBL] [Abstract][Full Text] [Related]
8. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
9. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
Ang KK; Zhang Q; Rosenthal DI; Nguyen-Tan PF; Sherman EJ; Weber RS; Galvin JM; Bonner JA; Harris J; El-Naggar AK; Gillison ML; Jordan RC; Konski AA; Thorstad WL; Trotti A; Beitler JJ; Garden AS; Spanos WJ; Yom SS; Axelrod RS
J Clin Oncol; 2014 Sep; 32(27):2940-50. PubMed ID: 25154822
[TBL] [Abstract][Full Text] [Related]
12. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
[TBL] [Abstract][Full Text] [Related]
13. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
Yom SS; Torres-Saavedra P; Caudell JJ; Waldron JN; Gillison ML; Xia P; Truong MT; Kong C; Jordan R; Subramaniam RM; Yao M; Chung CH; Geiger JL; Chan JW; O'Sullivan B; Blakaj DM; Mell LK; Thorstad WL; Jones CU; Banerjee RN; Lominska C; Le QT
J Clin Oncol; 2021 Mar; 39(9):956-965. PubMed ID: 33507809
[TBL] [Abstract][Full Text] [Related]
14. Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Urban D; Corry J; Solomon B; Lim AM; Fua T; Coleman A; D'Costa I; Tiong A; Liu C; Peters LJ; Rischin D
Head Neck; 2016 Apr; 38 Suppl 1():E1117-21. PubMed ID: 26461454
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis.
Swain M; Kannan S; Srinivasan S; Agarwal JP; Gupta T
Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):786-795. PubMed ID: 35387752
[TBL] [Abstract][Full Text] [Related]
16. Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin.
Swiecicki PL; Li P; Bellile E; Stucken C; Malloy K; Shuman A; Spector ME; Chinn S; Casper K; McLean S; Moyer J; Chepeha D; Wolf GT; Prince M; Bradford C; Nyati M; Eisbruch A; Worden FP; Jolly S; Mierzwa M
Head Neck; 2020 Aug; 42(8):1728-1737. PubMed ID: 31989702
[TBL] [Abstract][Full Text] [Related]
17. Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study.
Takemoto N; Seo Y; Nakahara S; Yoshioka Y; Teshima T; Fujii T; Isohashi F; Otani K; Yoshii T; Takenaka Y; Suzuki M; Fukusumi T; Hanamoto A; Yasui T; Michiba T; Yamamoto Y; Shimamoto S; Tanaka H; Tatsumi M; Ogawa K; Inohara H
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):403-411. PubMed ID: 33373656
[TBL] [Abstract][Full Text] [Related]
18. nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.
Oppelt P; Ley J; Daly M; Rich J; Paniello R; Jackson RS; Pipkorn P; Liu J; Gay H; Palka K; Neupane P; Powell S; Spanos WC; Gitau M; Zevallos J; Thorstad W; Adkins D
Med Oncol; 2021 Mar; 38(4):35. PubMed ID: 33683482
[TBL] [Abstract][Full Text] [Related]
19. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
[TBL] [Abstract][Full Text] [Related]
20. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
